周红, 刘鑫, 郑江. 脓毒症治疗——挑战与机遇并存[J]. 第三军医大学学报, 2013, 35(2): 91-94. [2]Horwitz A H, Leigh S D, Abrahamson S, et al. Expression and characterization of cysteine-modified variants of an amino-terminal fragment of bactericidal/permeability-increasing protein[J]. Protein Expr Purif, 1996, 8(1): 28-40. [3]Chiu J, March P E, Lee R, et al. Site-directed, Ligase-Independent Mutagenesis (SLIM): a single-tube methodology approaching 100% efficiency in 4 h[J]. Nucleic Acids Res, 2004, 32(21): e174. [4]王慧娟, 何云燕, 夏云, 等. 多重耐药鲍曼不动杆菌 gyrA 基因高效反义肽核酸序列筛选及其体外抗菌活性观察[J]. 第三军医大学学报, 2013, 35(14): 1442-1446. [5] Angus D C, van-der-Poll T. Severe sepsis and septic shock[J]. N Engl J Med, 2013, 369(9): 840-851. [6]Alexander S, Bramson J, Foley R, et al. Protection from endotoxemia by adenoviral-mediated gene transfer of human bactericidal/permeability-increasing protein[J]. Blood, 2004, 103(1): 93-99. [7]Holweg A, Schnare M, Gessner A. The bactericidal/permeability-increasing protein (BPI) in the innate defence of the lower airways[J]. Biochem Soc Trans, 2011, 39(4): 1045-1050. [8]Domingues M M, Santos N C, Castanho M A. Antimicrobial peptide rBPI21: a translational overview from bench to clinical studies[J]. Curr Protein Pept Sci, 2012, 13(7): 611-619. [9]Srivastava A, Casey H, Johnson N, et al. Recombinant bactericidal/permeability-increasing protein rBPI21 protects against pneumococcal disease[J]. Infect Immun, 2007, 75(1): 342-349. [10]Schlag G, Redl H, Davies J, et al. Protective effect of bactericidal/permeability-increasing protein (rBPI21) in baboon sepsis is related to its antibacterial, not antiendotoxin, properties[J]. Ann Surg, 1999, 229(2): 262-271. [11]Levin M, Quint P A, Goldstein B, et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group[J]. Lancet, 2000, 356(9234): 961-967. [12]Demetriades D, Smith J S, Jacobson L E, et al. Bactericidal/permeability-increasing protein (rBPI21) in patients with hemorrhage due to trauma: results of a multicenter phase II clinical trial. rBPI21 Acute Hemorrhagic Trauma Study Group[J]. J Trauma, 1999, 46(4): 667-677. [13]Vandamme D, Landuyt B, Luyten W, et al. A comprehensive summary of LL-37, the factotum human cathelicidin peptide[J]. Cell Immunol, 2012, 280(1): 22-35. [14]Osmundson J, Montero-Diez C, Westblade L F, et al. Promoter-specific transcription inhibition in Staphylococcus aureus by a phage protein[J]. Cell, 2012, 151(5): 1005-1016. [15]Nemeth K, Leelahavanichkul A, Yuen P S, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production[J]. Nat Med, 2009, 15(1): 42-49.
[2]
贺贞,林东子,李观强,等.H5N1亚型禽流感病毒NS1蛋白多克隆抗体的制备及鉴定[J].第三军医大学学报,2012,34(16):1691. [2]房兆飞,龚丽莎,胡厚源,等.125I标记融合蛋白TAP-SSL5在健康大耳兔体内的药代动力学研究[J].第三军医大学学报,2012,34(21):2145. Fang Zhaofei,Gong Lisha,Hu Houyuan,et al.Pharmacokinetics of 125I-TAP-SSL5 in normal rabbits[J].J Third Mil Med Univ,2012,34(07):2145. [3]张佩,陈婷婷,叶枫,等.表达SDF-1/HOXB4融合基因的间充质干细胞对造血干细胞体外扩增及干性维持的作用[J].第三军医大学学报,2013,35(07):589. Zhang Pei,Chen Tingting,Ye Feng,et al.Effect of SDF-1/HOXB4 fusion gene-modified mesenchymal stem cells on amplification and stemness maintenance of hematopoietic stem cells in vitro[J].J Third Mil Med Univ,2013,35(07):589. [4]郭晓姝,李洪涛,方海立,等.小鼠IFIT1多克隆抗体的制备[J].第三军医大学学报,2007,29(15):1462. GUO Xiao-shu,LI Hong-tao,FANG Hai-li,et al.Preparation of polyclonal antibody of mouse IFIT1[J].J Third Mil Med Univ,2007,29(07):1462. [5]李新伦,何娅妮,杨聚荣,等.人cubilin蛋白功能片段原核表达系统的建立[J].第三军医大学学报,2006,28(10):1016. [6]雒喜忠,王阁,郑继军,等.RAI16基因真核表达载体的构建及在HepG2中的表达[J].第三军医大学学报,2009,31(17):1620. LUO Xi-zhong,WANG Ge,ZHENG Ji-jun,et al.Construction of eukaryotic expression vector for RAI16 and its expression in HepG2 cells[J].J Third Mil Med Univ,2009,31(07):1620. [7]曲小龙,胡厚源,李敏,等.抗炎、抗凝双效融合蛋白TAP-SSL5表达载体的构建及其功能研究[J].第三军医大学学报,2010,32(01):5. Qu Xiaolong,Hu Houyuan,Li Min,et al.Construction of a novel fusion protein TAP-SSL5 and evaluation of its function as anti-inflammatory and anticoagulant protein in vitro[J].J Third Mil Med Univ,2010,32(07):5. [8]梁宇佳,缪殿南,闫国和,等.含uPA裂解位点的人sTrail融合基因的构建及其原核蛋白表达与纯化[J].第三军医大学学报,2011,33(08):789. Liang Yujia,Miao Diannan,Yan Guohe,et al.Construction, prokaryotic expression and purification of human sTrail fusion protein activated by uPA[J].J Third Mil Med Univ,2011,33(07):789. [9]程彦,房兆飞,曲小龙,等.融合蛋白TAP-SSL5对人血小板功能的影响[J].第三军医大学学报,2012,34(06):477. Cheng Yan,Fang Zhaofei,Qu Xiaolong,et al.Effect of TAP-SSL5 fusion protein on human platelet functions in vitro and in vivo [J].J Third Mil Med Univ,2012,34(07):477. [10]龚丽莎,房兆飞,胡厚源,等.融合蛋白TAP-SSL5对血小板与粒细胞结合的影响[J].第三军医大学学报,2013,35(08):754. Gong Lisha,Fang Zhaofei,Hu Houyuan,et al.Effect of TAP-SSL5 fusion protein on binding of human platelets to neutrophils[J].J Third Mil Med Univ,2013,35(07):754.
